Skip to Content
Merck
CN
All Photos(1)

Documents

454202

Sigma-Aldrich

8-Methoxymethyl-3-isobutyl-1-methylxanthine

A cell-permeable selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I; IC₅₀ = 4 µM).

Synonym(s):

8-Methoxymethyl-3-isobutyl-1-methylxanthine, 8-Methoxymethyl-IBMX

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C12H18N4O3
CAS Number:
Molecular Weight:
266.30
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (TLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white

solubility

ethanol: 2 mg/mL
DMSO: 5 mg/mL

shipped in

ambient

storage temp.

10-30°C

InChI

1S/C12H18N4O3/c1-7(2)5-16-10-9(11(17)15(3)12(16)18)13-8(14-10)6-19-4/h7H,5-6H2,1-4H3,(H,13,14)

InChI key

NBLBCGUCPBXKOV-UHFFFAOYSA-N

General description

A cell-permeable selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I; IC50 = 4 µM).
A cell-permeable, selective inhibitor of Ca2+-calmodulin-dependent phosphodiesterase (PDE I, IC50 = 4 µM).

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PDE 1
Product does not compete with ATP.
Reversible: no
Target IC50: 4 µM against Ca2+-calmodulin-dependent phosphodiesterase (PDE I)

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution aliquot and freeze at -20°C. Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Jackson, E.K., et al. 1997. J. Cardiovasc. Pharmacol. 30, 798.
Ahn, H.S., et al. 1989. Biochem. Pharmacol.38, 3331.
Han, P., et al. 1989. J. Biol. Chem.274, 22337.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E K Jackson et al.
Journal of cardiovascular pharmacology, 30(6), 798-801 (1998-01-22)
The objective this investigation was to determine the relative importance of type I, III, and IV phosphodiesterases in the regulation of cyclic adenosine monophosphate (cAMP) in the renal circulation. In the first experimental series, four groups of isolated rat kidneys
H S Ahn et al.
Biochemical pharmacology, 38(19), 3331-3339 (1989-10-01)
In this study three forms of cyclic nucleotide phosphodiesterase (PDE) isolated from rabbit aorta were pharmacologically characterized, and the consequence of selective inhibition of calmodulin-stimulated PDE (CaM-PDE) and cGMP specific PDE (cG-PDE) was evaluated using PDE inhibitors. The cG-PDE (F1)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service